2026-04-17T04:23:24Zhttps://recercat.cat/oai/request

oai:recercat.cat:10256/151002024-06-18T13:36:03Zcom_2072_452955com_2072_2054col_2072_452958

00925njm 22002777a 4500 dc Vert Company, Anna author Castro Gallegos, Jessica author Ribó i Panosa, Marc author Vilanova i Brugués, Maria author Benito i Mundet, Antoni author 2018 Ovarian cancer has the highest mortality rate among all the gynecological cancers. This is mostly due to the resistance of ovarian cancer to current chemotherapy regimens. Therefore, it is of crucial importance to identify the molecular mechanisms associated with chemoresistance. Methods: NCI/ADR-RES is a multidrug-resistant cell line that is a model for the study of drug resistance in ovarian cancer. We carried out a microarray-derived transcriptional profiling analysis of NCI/ADR-RES to identify differentially expressed genes relative to its parental OVCAR-8. Results: Gene-expression profiling has allowed the identification of genes and pathways that may be important for the development of drug resistance in ovarian cancer. The NCI/ADR-RES cell line has differential expression of genes involved in drug extrusion, inactivation, and efficacy, as well as genes involved in the architectural and functional reorganization of the extracellular matrix. These genes are controlled through different signaling pathways, including MAPK–Akt, Wnt, and Notch. Conclusion: Our findings highlight the importance of using orthogonal therapies that target completely independent pathways to overcome mechanisms of resistance to both classical chemotherapeutic agents and molecularly targeted drugs http://hdl.handle.net/10256/15100 Ovaris -- Càncer Ovaries -- Cancer Resistència als medicaments Drug resistance Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance